Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359614 | 1.00 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL133918 | 0.86 | KMT2A (0.33) | DGAT1 | |
| SCHEMBL7865780 | 0.86 | KMT2A (0.33) | DGAT1 | |
| SCHEMBL206812 | 0.86 | KMT2A (0.33) | DGAT1 | |
| SCHEMBL15305057 | 0.84 | — | — | |
| SCHEMBL12231419 | 0.81 | TDP1 (0.33) | DGAT1 | |
| SCHEMBL18882631 | 0.81 | TDP1 (0.33) | DGAT1 | |
| SCHEMBL2348113 | 0.81 | TDP1 (0.33) | DGAT1 | |
| Sulfuric Acid SCHEMBL28494040 | 0.80 | CA12 (0.33) | — | |
| SCHEMBL15084705 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293587-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | Technische Universität München (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-3849997-B1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | UNIV MUENCHEN TECH (DE) | 2024-05-01 | — | — | EP | disclosed |
| US-11944691-B2 | CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity | Technische Universität München (DE) | 2024-04-02 | — | — | US | disclosed |
| CN-111868060-B | Dihydropyridino phthalazinone derivatives, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220040339-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | Technische Universität München (DE) | 2022-02-10 | — | — | US | disclosed |
| WO-2019174607-A1 | DIHYDROPYRIDOPHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海艾力斯医药科技有限公司 | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040339-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | CXCR4, CXCR3, ACKR3 | DGAT1 2918/4885 |
| US-20240293587-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | CXCR4, CXCR3, ACKR3 | DGAT1 2918/4885 |
| US-11944691-B2 | CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity | CXCR4, CXCR3, ACKR3 | DGAT1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.